Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists
about
The Role of PPARs in CancerDAX-1 acts as a novel corepressor of orphan nuclear receptor HNF4alpha and negatively regulates gluconeogenic enzyme gene expressionObesity and insulin resistanceFoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-activated receptor gamma activation in adipose tissueGenes, diet and type 2 diabetes mellitus: a reviewNuclear receptor corepressors and PPARgammaMesenchymal Stem Cells and Metabolic Syndrome: Current Understanding and Potential Clinical ImplicationsThe glycaemic outcomes of Cinnamon, a review of the experimental evidence and clinical trialsLinking obesity with type 2 diabetes: the role of T-betGQ-16, a Novel Peroxisome Proliferator-activated Receptor (PPAR ) Ligand, Promotes Insulin Sensitization without Weight GainActivation of peroxisome proliferator-activated receptor-gamma stimulates the growth arrest and DNA-damage inducible 153 gene in non-small cell lung carcinoma cellsOmega-3 Fatty Acids and PPARgamma in CancerOsteopontin is required for the early onset of high fat diet-induced insulin resistance in miceMechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitizationTroglitazone-induced changes in adiponectin do not affect endothelial function in diabetes.Transcriptome alteration in the diabetic heart by rosiglitazone: implications for cardiovascular mortality.Chlorinated persistent organic pollutants, obesity, and type 2 diabetesSynthesis and anti-obesity effects in vivo of Crotadihydrofuran C as a novel PPARγ antagonist from Crotalaria albidaInsulin, cognition, and dementiaRole of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver diseaseMolecular Characterization of the Tumor Suppressor Candidate 5 Gene: Regulation by PPARgamma and Identification of TUSC5 Coding Variants in Lean and Obese Humans.Energy restriction as an antitumor target of thiazolidinediones.Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets.Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats.Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation.CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models.AMPK-dependent repression of hepatic gluconeogenesis via disruption of CREB.CRTC2 complex by orphan nuclear receptor small heterodimer partner.Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver.AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome.Management of obesity in patients with Type 2 diabetes.The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity.Structural genomics in endocrinology.Multi-tissue, selective PPARγ modulation of insulin sensitivity and metabolic pathways in obese rats.Angiotensin AT(2) receptor contributes towards gender bias in weight gainPPARG regulates gonadotropin-releasing hormone signaling in LbetaT2 cells in vitro and pituitary gonadotroph function in vivo in mice.Novel insulin sensitizers: pharmacogenomic aspects.Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects.The Effect of Cinnamon on Glucose of Type II Diabetes Patients.Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.Expression and functional activity of PPARgamma in pancreatic beta cells.
P2860
Q21342955-C5AF1C17-778D-450E-9E70-60A71217A026Q24320012-79528F43-545B-4435-B43E-269E0E1E1F0BQ24607078-6BA150CF-AA8E-4E50-80A2-5F5AFAE7D5B6Q24643006-1D6810C2-0201-4E14-9AD2-B6E23F87BB12Q24672249-BE6FF344-80D3-4ED2-9862-67883EAC1645Q25257827-C5E6F2B4-0D9B-43BA-9AA4-79F6722A6A1DQ26745520-02A41572-6C60-4EC1-8122-3D07AFCAB521Q26782181-99A61807-AB0F-45AE-B4DA-AB268DD4705DQ26830915-0F678CA0-5C8B-4C37-B437-A39A164BE312Q27679090-172A269C-1708-4351-B360-9422AE67C015Q28214426-CA64EC8F-359B-4828-967F-ADDEAC8B9E9EQ28292907-4069A4B1-E40F-4A14-8E98-15CD809CB8DEQ28748481-5779794C-390A-4AF5-AD1D-DAC34C10C22DQ29028203-2E75739B-058B-44E4-9DAE-0BF11893358EQ33220980-D08357F2-F87B-4D0E-9995-91EB84F46833Q33354126-5EE73A6B-95C6-4374-B4F7-44972C514F5EQ33569410-8E8183A7-107A-4A2F-A6EA-931A997AA613Q33594205-51EC8A1B-FD92-4EEC-87F3-913CC672562AQ33604874-FE328397-72C3-4B02-BE25-B6959E411D11Q33607697-7110A7E4-05FE-4C4E-A797-E7683FC1E9FCQ33696469-4FAB02E2-D4D0-41E6-A459-C6B7704E3B5BQ33744668-B47DEF0A-83BC-43AB-A2F8-33F376E639A4Q33808884-C0DB4185-2970-45DB-B49A-7853B14E32FBQ33836877-7AAC68D0-13B5-4FCA-B828-C8AFBBF02868Q34061979-1884F2EB-F6F2-433E-B9D9-C78219DE61DEQ34067485-39AD0CD0-EBE7-4797-A80A-1E9962441C19Q34186447-8C68D2BA-CADD-4FE1-BAD7-723FB6BFD6B2Q34235817-EE390074-5D3C-4459-B3BA-4DDAB3AE9C55Q34310675-62B3785D-4A5F-4730-9655-AC2E618939F2Q34319377-87C01F2B-7A45-4D40-AC64-99BF4C0957C8Q34348367-68271E47-779A-4FD5-B751-B05CDF073A43Q34448292-A3E9D0AD-F578-4E94-94A8-0F66F45BCA7FQ34501727-B7C3FE02-2EBE-4B92-B1BA-A6B40D007243Q34558074-D5CEA73A-D77F-4088-A163-AB98D51348BEQ34594089-9A8B50E7-01E6-4F46-91AF-B65753BE6DC2Q34609164-30556B09-FB8B-4D06-81E8-0BC13C287353Q34655064-13D9D5CE-DDCD-465F-A2E7-C544A25516BEQ34661198-E813DEB5-8627-4993-A3C9-BA758DC37AB0Q34790967-EBC7565C-D767-49BC-BA93-D6D49A77C9F4Q35047497-7325FFD5-506E-46C5-97DE-393E0924576A
P2860
Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Treatment of insulin resistanc ...... ivated receptor gamma agonists
@ast
Treatment of insulin resistanc ...... ivated receptor gamma agonists
@en
Treatment of insulin resistanc ...... ivated receptor gamma agonists
@nl
type
label
Treatment of insulin resistanc ...... ivated receptor gamma agonists
@ast
Treatment of insulin resistanc ...... ivated receptor gamma agonists
@en
Treatment of insulin resistanc ...... ivated receptor gamma agonists
@nl
prefLabel
Treatment of insulin resistanc ...... ivated receptor gamma agonists
@ast
Treatment of insulin resistanc ...... ivated receptor gamma agonists
@en
Treatment of insulin resistanc ...... ivated receptor gamma agonists
@nl
P2860
P356
P1476
Treatment of insulin resistanc ...... ivated receptor gamma agonists
@en
P2860
P304
P356
10.1172/JCI10843
P407
P577
2000-08-01T00:00:00Z